5 results match your criteria: "Yonaha Okanoue Hospital[Affiliation]"
Efficacy, safety, and tissue penetration of solithromycin in Japanese patients with otorhinolaryngological infections.
Auris Nasus Larynx
April 2024
Department of Otorhinolaryngology, Yonaha Okanoue Hospital, Japan.
Article Synopsis
- The research aimed to evaluate solithromycin's effectiveness, safety, and ability to penetrate tissues in treating ear, nose, and throat infections through three distinct studies.
- The tissue penetration study involved 17 patients who received solithromycin before tissue removal, while the open-label study included 55 patients with various infections and assessed clinical responses post-treatment.
- The non-inferiority study compared solithromycin to high-dose cefcapene-pivoxil in 283 patients with acute rhinosinusitis, focusing on clinical outcomes after treatment.
Neurodevelopmental outcome after antenatal therapy for fetal supraventricular tachyarrhythmia: 3-year follow-up of multicenter trial.
Ultrasound Obstet Gynecol
January 2023
Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
Objectives: Although many studies have supported the efficacy of transplacental treatment for fetal supraventricular tachyarrhythmia, the long-term neurodevelopmental outcome after antenatal antiarrhythmic treatment is not well understood. The aim of this study was to investigate the prognosis and neurodevelopmental outcome at 36 months of corrected age and the incidence of tachyarrhythmia after birth, following protocol-defined antenatal therapy for fetal supraventricular tachyarrhythmia.
Methods: This was a 3-year follow-up study of a multicenter trial that evaluated the efficacy and safety of protocol-defined transplacental treatment for fetal supraventricular tachycardia (SVT) and atrial flutter (AFL).
Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition (GLIM) diagnosis of malnutrition.
Clin Nutr
June 2022
Department of Biobehavioral Health Science, University of Pennsylvania School of Nursing, Philadelphia, PA, USA.
The Global Leadership Initiative on Malnutrition (GLIM) provides consensus criteria for the diagnosis of malnutrition that can be widely applied. The GLIM approach is based on the assessment of three phenotypic (weight loss, low body mass index, and low skeletal muscle mass) and two etiologic (low food intake and presence of disease with systemic inflammation) criteria, with diagnosis confirmed by any combination of one phenotypic and one etiologic criterion fulfilled. Assessment of muscle mass is less commonly performed than other phenotypic malnutrition criteria, and its interpretation may be less straightforward, particularly in settings that lack access to skilled clinical nutrition practitioners and/or to body composition methodologies.
View Article and Find Full Text PDFGuidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition diagnosis of malnutrition.
JPEN J Parenter Enteral Nutr
August 2022
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
The Global Leadership Initiative on Malnutrition (GLIM) provides consensus criteria for the diagnosis of malnutrition that can be widely applied. The GLIM approach is based on the assessment of three phenotypic (weight loss, low body mass index, and low skeletal muscle mass) and two etiologic (low food intake and presence of disease with systemic inflammation) criteria, with diagnosis confirmed by any combination of one phenotypic and one etiologic criterion fulfilled. Assessment of muscle mass is less commonly performed than other phenotypic malnutrition criteria, and its interpretation may be less straightforward, particularly in settings that lack access to skilled clinical nutrition practitioners and/or to body composition methodologies.
View Article and Find Full Text PDFBackground: Cancer cachexia is a syndrome characterized by anorexia and decreased body weight. This study evaluated the efficacy and safety of anamorelin, an orally active, selective ghrelin receptor agonist, in patients with cancer cachexia and a low body mass index (BMI).
Methods: This multicenter, open-label, single-arm study enrolled Japanese patients with non-small cell lung cancer or gastrointestinal cancer with cancer cachexia (BMI < 20 kg/m , involuntary weight loss > 2% in the last 6 months, and anorexia).